MWNA
ADMS

Marshall Wace North America’s Adamas Pharmaceuticals ADMS Stock Holding History

Marshall Wace North America’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,525
Closed -$98K – 2032
2018
Q4 		$98K Buy
+11,525
New +$150K ﹤0.01% 1087

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Marshall Wace North America's ADMS Position: Q1 2019 in Review

Marshall Wace North America sold out of Adamas Pharmaceuticals (ADMS) in Q1 2019, closing a stake of 11,525 shares — an estimated $98K sold.

Marshall Wace North America first reported a position in ADMS in Q4 2018 and held it in 1 quarter. The position peaked at $98K in Q4 2018. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • Marshall Wace North America reported no remaining Adamas Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 11,525 Adamas Pharmaceuticals shares in Q1 2019, an estimated $98K.
  • Marshall Wace North America first reported a position in Adamas Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Marshall Wace North America's Adamas Pharmaceuticals position peaked at $98K in Q4 2018.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.